Traditionally, early-stage and late-stage process development have been done separately, with early-stage mostly focused on material production and late-stage on process intensification. As more molecules in development fall under an orphan or fast-track indication, the traditional approach of linear development stages can be counterproductive—not to mention expensive—due to investing resources in perfecting a process prior to early clinical phase success. Addressing some of the aspects of late-stage process development during the initial process development can help save valuable time following phase 1 clinical studies
Download our white paper for insights on:
- Seven considerations when combining early- and late-stage process development for fast-track drugs
- Late-stage development to commercialization
- When it comes to speed, Integrated process development counts
More from Curia
Ensuring the safety and efficacy of pharmaceutical products is paramount in the healthcare industry, making the FDA's Quality Management Maturity (QMM) program and CDER's proposed rating system crucial for Contract Development and Manufacturing Organ...